Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | MANBA | O00462 | 1/20 | 0.39 |
| ▸ | HK1 | P19367 | 1/20 | 0.38 |
| ▸ | HK2 | P52789 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10871363 | 1.00 | CYP1A2 (0.41) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL10877634 | 1.00 | CYP1A2 (0.41) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL3494618 | 0.96 | LGALS3 (0.41) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL29365683 | 0.82 | LGALS3 (0.41) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL30955333 | 0.82 | LGALS3 (0.41) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL27701497 | 0.81 | MEN1 (0.35) | ALDH1A1RAB9ATP53CYP3A4HIF1A | |
| SCHEMBL8499800 | 0.80 | NPC1 (0.39) | ALDH1A1NPC1RAB9A | |
| SCHEMBL7083505 | 0.80 | NPC1 (0.39) | ALDH1A1NPC1RAB9A | |
| SCHEMBL9573470 | 0.80 | ALDH1A1 (0.42) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL28237927 | 0.78 | SLC5A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5301885-A | — | — | None | — | — | JP | disclosed |
| CN-118490751-B | Composition of hypoglycemic plant extract and preparation method thereof | 广州科望角生物科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118490751-A | Composition of hypoglycemic plant extract and preparation method thereof | 广州科望角生物科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118001318-A | Blood sugar control composition containing mulberry leaf and cinnamon extract and application thereof | 广州科望角生物科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4212541-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES AND THEIR INTERMEDIATES | Genzyme Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-11279725-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-10781434-B2 | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders | VALERION THERAPEUTICS, LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200224184-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF GLYCOGEN STORAGE DISEASES AND GLYCOGEN METABOLISM DISORDERS | VALERION THERAPEUTICS, LLC | 2020-07-16 | — | — | US | disclosed |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2020-07-09 | — | — | US | disclosed |
| WO-2010075010-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20080301826-A1 | NOVEL BETA-ACTIN AND RPS21 PROMOTERS AND USES THEREOF | GENZYME CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-7423135-B2 | Expression vector comprising rodent regulatory sequences for use as gene expression control tools in genetic engineering | GENZYME CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1639112-A2 | NOVEL BETA-ACTIN AND RPS21 PROMOTERS AND USES THEREOF | Genzyme Corporation (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050026252-A1 | Expression vector comprising rodent regulatory sequences for use as gene expression control tools in genetic engineering | GENZYME CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005000888-A2 | NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF | GENZYME CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-0871854-A2 | MEDIUM FOR DETECTING ENTEROCOCCI IN A SAMPLE | IDEXX LABORATORIES, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1996015435-A2 | MEDIUM FOR DETECTING ENTEROCOCCI IN A SAMPLE | IDEXX LABORATORIES, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| JP-H05301885-A | PRODUCTION OF ALPHA-D-GLUCOPYRANOSIDE DERIVATIVE | TAOKA CHEM CO LTD | 1993-11-16 | — | — | JP | disclosed |
| EP-0085348-A1 | Reagents for the determination of enzymes | AMERICAN HOECHST CORPORATION (US) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | CYP1A2 4094/4885NFKB1 4251/4885THPO 1718/4885 |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | CYP1A2 4094/4885NFKB1 4251/4885THPO 1718/4885 |
| US-11279725-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | CYP1A2 4094/4885NFKB1 4251/4885THPO 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.